Argeris N Karabelas - Net Worth and Insider Trading
Argeris N Karabelas Net Worth
The estimated net worth of Argeris N Karabelas is at least $303,497 dollars as of 2024-07-16. Argeris N Karabelas is the Director of Bausch Health Companies Inc and owns about 20,726 shares of Bausch Health Companies Inc (BHC) stock worth over $154,409. Argeris N Karabelas is the Director of Regenxbio Inc and owns about 11,286 shares of Regenxbio Inc (RGNX) stock worth over $149,088. Argeris N Karabelas is also the Director of Vanda Pharmaceuticals Inc and owns about 0 shares of Vanda Pharmaceuticals Inc (VNDA) stock worth over $0. Details can be seen in Argeris N Karabelas's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Argeris N Karabelas has not made any transactions after 2024-07-01 and currently still holds the listed stock(s).
Transaction Summary of Argeris N Karabelas
Argeris N Karabelas Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Argeris N Karabelas owns 5 companies in total, including Regenxbio Inc (RGNX) , Bausch Health Companies Inc (BHC) , and Rocket Pharmaceuticals Inc (RCKT) among others .
Click here to see the complete history of Argeris N Karabelas’s form 4 insider trades.
Insider Ownership Summary of Argeris N Karabelas
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RGNX | Regenxbio Inc | 2024-07-01 | director |
| BHC | Bausch Health Companies Inc | 2017-05-05 | director |
| RCKT | Rocket Pharmaceuticals Inc | 2015-02-17 | director & 10 percent owner |
 | | 2010-03-12 | director & Chairman of the Board |
| | 2009-07-23 | other: See remarks below. |
Argeris N Karabelas Latest Holdings Summary
Argeris N Karabelas currently owns a total of 3 stocks. Among these stocks, Argeris N Karabelas owns 20,726 shares of Bausch Health Companies Inc (BHC) as of August 11, 2016, with a value of $154,409 and a weighting of 50.88%. Argeris N Karabelas owns 11,286 shares of Regenxbio Inc (RGNX) as of July 1, 2024, with a value of $149,088 and a weighting of 49.12%. Argeris N Karabelas also owns 0 shares of Vanda Pharmaceuticals Inc (VNDA) as of March 12, 2010, with a value of $0 and a weighting of 0%.
Latest Holdings of Argeris N Karabelas
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BHC | Bausch Health Companies Inc | 2016-08-11 | 20,726 | 7.45 | 154,409 |
| RGNX | Regenxbio Inc | 2024-07-01 | 11,286 | 13.21 | 149,088 |
| VNDA | Vanda Pharmaceuticals Inc | 2010-03-12 | 0 | 6.11 | 0 |
Holding Weightings of Argeris N Karabelas
Argeris N Karabelas Form 4 Trading Tracker
According to the SEC Form 4 filings, Argeris N Karabelas has made a total of 0 transactions in Bausch Health Companies Inc (BHC) over the past 5 years. The most-recent trade in Bausch Health Companies Inc is the acquisition of 4,000 shares on August 11, 2016, which cost Argeris N Karabelas around $98,600.
According to the SEC Form 4 filings, Argeris N Karabelas has made a total of 1 transactions in Regenxbio Inc (RGNX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Regenxbio Inc is the sale of 10,000 shares on July 1, 2024, which brought Argeris N Karabelas around $112,700.
According to the SEC Form 4 filings, Argeris N Karabelas has made a total of 0 transactions in Vanda Pharmaceuticals Inc (VNDA) over the past 5 years. The most-recent trade in Vanda Pharmaceuticals Inc is the sale of 200,000 shares on March 12, 2010, which brought Argeris N Karabelas around $2 Million.
Insider Trading History of Argeris N Karabelas
- 1
Argeris N Karabelas Trading Performance
GuruFocus tracks the stock performance after each of Argeris N Karabelas's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Argeris N Karabelas is -26.5%. GuruFocus also compares Argeris N Karabelas's trading performance to market benchmark return within the same time period. The performance of stocks bought by Argeris N Karabelas within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Argeris N Karabelas's insider trading performs compared to the benchmark.
Performance of Argeris N Karabelas
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 14.58 | | | | | |
| Relative Return to S&P 500(%) | 17.23 | | | | | |
Argeris N Karabelas Ownership Network
Argeris N Karabelas Owned Company Details
What does Regenxbio Inc do?
Who are the key executives at Regenxbio Inc?
Argeris N Karabelas is the director of Regenxbio Inc. Other key executives at Regenxbio Inc include director & See Remarks Kenneth T. Mills , Chief Medical Officer Steve Pakola , and See Remarks Vittal Vasista .
Regenxbio Inc (RGNX) Insider Trades Summary
Over the past 18 months, Argeris N Karabelas made 1 insider transaction in Regenxbio Inc (RGNX) with a net sale of 10,000. Other recent insider transactions involving Regenxbio Inc (RGNX) include a net sale of 150,000 shares made by Kenneth T. Mills , a net sale of 12,878 shares made by Steve Pakola ,
In summary, during the past 3 months, insiders sold 25,000 shares of Regenxbio Inc (RGNX) in total and bought 0 shares, with a net sale of 25,000 shares. During the past 18 months, 172,878 shares of Regenxbio Inc (RGNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 172,878 shares.
Regenxbio Inc (RGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regenxbio Inc Insider Transactions
Argeris N Karabelas Mailing Address
Above is the net worth, insider trading, and ownership report for Argeris N Karabelas. Currently GuruFocus does not have mailing address information for Argeris N Karabelas.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
